452339-73-0

Basic information

• Product Name: 2-Oxazolidinone, 5-(2,2-diMethyl-4H-1,3-benzodioxin-6-yl)-, (5R)-
• Synonyms: 2-Oxazolidinone, 5-(2,2-diMethyl-4H-1,3-benzodioxin-6-yl)-, (5R)-;(5R)-2-Oxazolidinone, 5-(2,2-diMethyl-4H-1,3-benzodioxin-6-yl);(5R)-5-(2,2-DiMethyl-4H-1,3-benzodioxin-6-yl)-1,3-oxazolidin-2-one;(R)-5-(2,2-Dimethyl-4H-1,3-benzodioxin-6-yl)-1,3-oxazolidin-2-one
• CAS NO: 452339-73-0
• Molecular Formula: C₁₃H₁₅NO₄
• Molecular Weight: 249.2625
• EINECS: 1592732-453-0
• Product Categories: Intermediate
• Mol File: 452339-73-0.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 489.6±45.0 °C(Predicted)
• Appearance: /
• Density: 1.223±0.06 g/cm3(Predicted)
• Storage Temp.: Inert atmosphere,Store in freezer, under -20°C
• Solubility: Chloroform (Sparingly), Methanol (Slightly)
• PKA: 12.29±0.40(Predicted)
• CAS DataBase Reference: 2-Oxazolidinone, 5-(2,2-diMethyl-4H-1,3-benzodioxin-6-yl)-, (5R)-(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Oxazolidinone, 5-(2,2-diMethyl-4H-1,3-benzodioxin-6-yl)-, (5R)-(452339-73-0)
• EPA Substance Registry System: 2-Oxazolidinone, 5-(2,2-diMethyl-4H-1,3-benzodioxin-6-yl)-, (5R)-(452339-73-0)

Safety Data

• Hazardous Substances Data: 452339-73-0(Hazardous Substances Data)

Usage

Uses

Different sources of media describe the Uses of 452339-73-0 differently. You can refer to the following data:
1. (5R)-5-(2,2-diMethyl-4H-1,3-benzodioxin-6-yl)-2-Oxazolidinone is a reagent applied in the preparation of alkyl-linked di-phenyl aminoalcohols as long-acting β2 adrenergic receptor agonist. It is used as an antedrug.
2. R)-5-(2,2-Dimethyl-4H-1,3-benzodioxin-6-yl)-1,3-oxazolidin-2-one is a reagent applied in the preparation of alkyl-linked di-phenyl aminoalcohols as long-acting β2 adrenergic receptor agonist. An antedrug.

Upstream product

• 1761-61-1 5-bromosalicyclaldehyde 
• 2316-64-5 5-bromo-2-hydroxybenzyl alcohol 
• 52113-69-6 6-bromo-2,2-dimethyl-4H-benzo[1,3]dioxine 
• 54030-34-1 1-(2,2-dimethyl-4H-benzo[d][1,3]dioxan-6-yl)ethanone 
• 208925-08-0 (2R)-hydroxy-2-(2,2-dimethyl-4H-1,3-benzodioxine-6-yl)-ethylamine 
• 530-62-1 1,1'-carbonyldiimidazole 
• 452339-70-7 di-(tert-butyl) 2-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-oxoethyliminodicarbonate 
• 452339-71-8 tert-butyl 2-(2,2-dimethyl-4H-1,3-benzodioxane-6-yl)-2-carbonylethylcarbamate 
• 102293-80-1 2-bromo-1-(2,2-dimethyl-4H-benzo[d][1,3]dioxin-6-yl)ethanone 
• 452339-72-9 tert-butyl (2R)-2-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-hydroxyethylcarbamate 

Downstream Products

• 503068-36-8 (5R)-3-{6-[(2-{[(2,6-dichlorophenyl)methyl]oxy}ethyl)oxy]-hexyl}-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-1,3-oxazolidin-2-one 
• 503068-37-9 (2R)-hydroxy-2-(2,2-dimethyl-4Η-1,3-benzodioxole-6-yl)-N-3-[6-[2-[(2,6-dichlorophenyl)methoxy]ethoxy]hexyl]-ethylamine 
• 503068-34-6 4-[(1R)-2-({6-[(2-{[(2,6-dichlorophenyl)methyl]oxy}ethyl)oxy]-hexyl}-amino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol 
• 503070-58-4 4‐{(1R)‐2‐[(6‐{2‐[(2,6‐dichlorobenzyl)oxy]ethoxy}hexyl)amino]‐1‐hydroxyethyl}‐2‐(hydroxymethyl)phenol triphenylacetate 
• 686351-15-5 (1R)-2-{[6-({4-[3-(3-cyclopenten-1-ylsulfonyl)phenyl]butyl}oxy)hexyl]amino}-1-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)ethanol 
• 686351-14-4 (5R)-3-[6-({4-[3-(3-cyclopenten-1-ylsulfonyl)phenyl]butyl}oxy)hexyl]-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-1,3-oxazolidin-2-one 
• 686351-13-3 (5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-3-(6-{[4-(3-{[1-(2-propen-1-yl)-3-buten-1-yl]sulfonyl}phenyl)butyl]oxy}hexyl)-1,3-oxazolidin-2-one 
• 594862-17-6 (5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-3-(6-{[4-(3-methyl-5-nitrophenyl)-3-butyn-1-yl]oxy}hexyl)-1,3-oxazolidin-2-one 
• 503068-27-7 (5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-3-{6-[(2-{[(3-nitrophenyl)methyl]oxy}ethyl)oxy]hexyl}-1,3-oxazolidin-2-one 

Relevant articles and documents

Phenylethanolamine derivative and its preparation method and application

The invention relates to a phenylethanolamine derivative represented in the following formula 1. The phenylethanolamine derivative can serve as a beta 2 receptor agonist. The formula can be seen from the description.

PROCESS FOR THE PREPARATION OF VILANTEROL AND INTERMEDIATES THEREOF

An improved process for the preparation of vilanterol and pharmaceutically acceptable salts thereof is disclosed. More specifically the improved process for preparing intermediates for the preparation of vilanterol is disclosed.

PHENETHANOLAMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF RESPIRATORY DISEASES

The present invention relates to novel compounds of formula (I), to a process for their manufacture, to pharmaceutical compositions containing them, and to their use in therapy, in particular their use in the prophylaxis and treatment of respiratory diseases.